RBC Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $20
Chardan Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $20
Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $20
Lexeo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $23
J.P. Morgan Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating
Promising Therapeutic Advancements and Strategic Progression Support Buy Rating for Lexeo Therapeutics, Inc.
Chardan Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $22
Lexeo Therapeutics Price Target Maintained With a $23.00/Share by HC Wainwright & Co.
Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $22
Lexeo Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Lexeo Therapeutics, Maintains $23 Price Target
RBC Capital Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $20
Leerink Partners Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Cuts Target Price to $18
Lexeo Therapeutics Is Maintained at Buy by Chardan Capital
Lexeo Therapeutics Price Target Maintained With a $25.00/Share by Chardan Capital
Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC) and Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics Analyst Ratings
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $21
Lexeo Therapeutics, Inc. (LXEO) Gets a Buy From Stifel Nicolaus